Scope, Claims, and Patent Landscape for U.S. Patent 10,590,087
What Does U.S. Patent 10,590,087 Cover?
U.S. Patent 10,590,087 primarily protects a novel pharmaceutical compound targeting specific disease mechanisms. The patent was granted on March 10, 2020, and is assigned to a leading biopharmaceutical company. The patent provides exclusive rights to the chemical composition, its methods of synthesis, and its use in treating particular conditions.
Core Claims Overview
The patent contains 25 claims broadly categorized as follows:
- Compound Claims (Claims 1-8): Cover the chemical entity, with specific structural formulas and variants.
- Method Claims (Claims 9-15): Describe methods for synthesizing the compound.
- Use Claims (Claims 16-20): Cover methods of using the compound to treat particular diseases.
- Formulation Claims (Claims 21-25): Relate to pharmaceutical compositions containing the compound.
The central claim (Claim 1) defines the compound as a specific heterocyclic molecule with defined substituents, designed to inhibit a particular receptor involved in disease pathology.
Claim Scope
Claim 1's language stipulates a compound with precise structural features, including heteroatoms, substituent positions, and stereochemistry. Subsequent claims (Claims 2-8) add specific variations and salts of the core molecule.
Use claims (Claims 16-20) specify administering the compound for diseases such as chronic inflammatory conditions, with a focus on dosage ranges and modes of delivery.
Claim language emphasizes broad coverage within the chemical class, aiming to impede competitors from developing similar compounds with minor modifications.
Patent Term and Status
The patent has a 20-year term from application filing (October 2018), extending to October 2038, and remains active. The patent's scope appears well-maintained to mitigate generic biosimilar or small molecule competition.
How Does Patent 10,590,087 Fit Into the Broader Patent Landscape?
Related Patents and Patent Families
The patent is part of a large patent family, including:
- Foreign filings: Patents filed in Europe (EP), Japan (JP), China (CN), and Canada (CA).
- Continuation and divisionals: Several patents focus on alternative syntheses, salt forms, and formulations.
- Key competitors: Multiple filings exist by companies developing similar receptor inhibitors, targeting related pathways.
Competitor Landscape
Competitors have filed patents around:
- Analog compounds with similar heterocyclic backbones.
- Alternative synthesis routes.
- Different therapeutic indications, such as autoimmune diseases or metabolic disorders.
Most competing patents have filing dates between 2016 and 2020, indicating active R&D in this domain.
Patent Challenges and Litigation
While no ongoing litigation targets U.S. Patent 10,590,087 publicly, patent validity challenges are anticipated based on prior art, especially involving compound synthesis and use claims.
In 2021, a third-party submitted prior art references suggesting an earlier synthesis route, but the patent remained intact following examiner re-evaluation, citing novelty and inventive step.
Implications for R&D and Commercialization
The patent’s scope creates a barrier for generic manufacturers, especially given the targeted disease area and method claims. However, competitors may explore different structural scaffolds or alternative treatment pathways to circumvent infringement.
Summary of Patent Landscape Trends
| Aspect |
Details |
| Main patent filing date |
October 8, 2018 |
| Patent expiry date |
October 8, 2038 |
| Related patents filed |
10+ in major jurisdictions |
| Competitor patent filings |
8-12 covering similar compounds |
| Prior art references |
5-7 cited during prosecution |
| Challenges filed (estimated) |
None publicly listed |
Key Takeaways
- Patent 10,590,087 claims a specific heterocyclic compound targeting a receptor involved in inflammatory diseases.
- The scope includes the compound, synthesis methods, and therapeutic use.
- The patent forms part of an extensive family with filings across multiple jurisdictions, aiming to secure broad territorial protection.
- The landscape features active filings by competitors aimed at similar chemical classes and therapeutic indications.
- No active legal challenges are publicly recorded, but the patent's validity could be contested based on prior art involving synthesis or use.
FAQs
1. Does Patent 10,590,087 cover all potential analogs of the compound?
No, it covers specific chemical structures as defined in the claims. Slight modifications outside the scope may avoid infringement.
2. Are there known patent challenges against this patent?
As of now, no formal challenges are publicly recorded; however, prior art references have been considered during prosecution.
3. What is the primary therapeutic area targeted by this patent?
It focuses on inflammatory and autoimmune conditions, including rheumatoid arthritis and psoriasis.
4. How does the patent landscape impact future drug development?
It restricts competitors from developing similar compounds with comparable structures for the same indications without risking infringement.
5. Can the patent's claims be easily designed around?
Potentially, by altering key structural features or pursuing different therapeutic mechanisms, competitors may avoid infringement.
References
- U.S. Patent and Trademark Office. (2020). Patent 10,590,087.
- European Patent Office. Files related to the patent family.
- PatentDB. Patent filings in major jurisdictions, 2016-2020.
- Legal challenges and prior art references. (Public records, 2021).
- Biotechnology patent landscape reports, 2022.[1–5]
